Skip to main content

Table 3 Modulation of costimulatory and coregulatory molecule expression by iv-SIL

From: Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence

MFI (mean ± SD)

pDC

 

mDC

 
 

Pre

Post

p

Pre

Post

p

HLA-DR

1673.5 ± 525.4

1523.4 ± 531.1

0.0092

2867.8 ± 440.9

2661.0 ± 573.2

0.1507

CD83

548.5 ± 187.7

755.0 ± 683.6

0.3982

374.9 ± 108.1

620.7 ± 392.5

0.0865

CD86

714.7 ± 174.0

743.6 ± 139.0

0.6359

1462.2 ± 322.8

1303.2 ± 328.0

0.4298

ICOSL

554.1 ± 223.8

640.4 ± 209.8

0.5265

498.2 ± 257.8

501.2 ± 133.7

0.9219

PD-L1

316.1 ± 110.7

376.8 ± 111.7

0.1848

272.0 ± 68.9

326.1 ± 88.6

0.1311

HLA-G

356.7 ± 57.8

409.9 ± 62.3

0.0583

567.7 ± 120.5

587.5 ± 108.4

0.6944

IL-T4

2303.6 ± 632.8

2743.4 ± 718.6

0.0165

1797.7 ± 424.0

2294.4 ± 570.7

0.0669

CD39

349.7 ± 116.9

437.8 ± 143.6

0.0456

1516.8 ± 269.2

1761.7 ± 527.6

0.2601

PD-L1/CD86

0.447 ± 0.110

0.5217 ± 0.197

0.3830

0.189 ± 0.042

0.268 ± 0.116

0.0929

  1. PBMC were analyzed before and after iv-SIL treatment by flow cytometry, as described in the “Methods” section, and the overall analysis of HLA-DR, CD83, CD86, ICOSL, PD-L1, HLA-G, IL-T4, and CD39 expression (MFI, mean SD) as well as the PD-L1/CD86 ratio on mDC and pDC is reported. Italicized values denote significance
Back to article page

Transplantation Research

ISSN: 2047-1440

Contact us